CoChat

Mini-hearts for disease modeling and drug testing – process optimization versus biological functionality

Open access
Hecking, Jana, Cano-Jorge, Mariel, Passier, Robert, Rivera-Arbeláez, José Manuel · 2026 · Frontiers in Bioengineering and Biotechnology

The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index; 56 of the 84 sources its claims cite were checked for support.

Abstract

animal studies fail to fully recapitulate human cardiac physiology, highlighting the urgent need for more relevant human-based models. Engineered three-dimensional cardiac systems - including organoids, engineered heart tissues, and heart-on-chip platforms offer promising alternatives, providing structural and functional insights into cardiac biology. However, a critical limitation of these models is their inability to perform fluid pumping and relaxation, which together define fundamental heart function. Engineered cardiac chambers have emerged to address this gap, enabling physiologically relevant pressure-volume measurements and capturing both contractile and diastolic dynamics that mimic aspects of native cardiac hemodynamics. This mini-review examines the current state of engineered cardiac chambers and highlights their main design features. We discuss their applications in disease modeling and drug testing, and outline key factors influencing the optimization of these models, including balancing biological fidelity with process efficiency through modular design principles. Overall, engineered cardiac chambers represent a unique, powerful platform to improve mechanistic understanding of cardiac disease, offering significant potential to advance cardiovascular research and therapeutic development.

Overview

CoChat Summary

## TL;DR

This mini-review argues that engineered cardiac chambers (“mini-hearts”) are the most physiologically relevant 3D cardiac in vitro platforms because they can pump fluid and support pressure-volume (PV) readouts, making them especially useful for disease modeling and drug testing. It emphasizes that future progress depends on balancing biological functionality with process optimization, often through modular design.

## Key findings

  • Engineered cardiac chambers (ECCs) address a key limitation of other 3D cardiac models: they can perform fluid pumping and enable PV measurements, including contractile and diastolic dynamics.
  • The review identifies several design features that improve physiological relevance, including perfusion, valve integration, cardiomyocyte alignment, complex geometries, and functional readouts; however, perfusion is described as “critical and underrepresented.”
  • Existing ECCs have already shown drug responses to cardioactive compounds such as isoproterenol, nifedipine, vasopressin, carbachol, and phenylephrine, and have been used to model myocardial infarction, Friedreich’s ataxia, HFpEF, and structural arrhythmia.
  • The paper reports that the miniaturized ECC approach by Michas et al. is the most cell-efficient, using about 174,000 cells per ECC, while existing models span from about 174,000 to about 15 million cells per construct; the highest performing model reports an ejection fraction of about 6%, below the physiological range of 50%–70%.

## Methods

  • This is a mini-review of existing engineered cardiac chamber platforms, not an original experimental study.
  • The review synthesizes previously published ECC models, focusing on fabrication processes, cell types and density, throughput, PV readouts, and applications in disease modeling and drug testing.
  • The main analysis is a qualitative comparison of design trade-offs between biological functionality and process optimization, with attention to modular design principles and context-of-use.

## Limitations

  • The paper states that no existing platform excels equally in all dimensions, and that trade-offs are unavoidable between process efficiency and physiological complexity.
  • The text notes that simultaneous PV measurements are currently limited to invasive micro-catheter systems adapted from in vivo mouse experiments, and that these may be inaccurate in cell culture media and incompatible with electrical pacing.
  • Evident from the text: this is a narrative mini-review rather than a systematic review, so the selection and weighting of examples appear qualitative rather than based on a formally described search or meta-analysis.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3389/fbioe.2025.1719533

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

FIGURE 1 ECC paradigm. Trade-off between focusing on process optimization (blue) and biological functionality (green) when designing ECC models for disease modeling and drug testing applications. Modular design principles (charcoal) can act as regulator to keep the two in balance.
FIGURE 1 ECC paradigm. Trade-off between focusing on process optimization (blue) and biological functionality (green) when designing ECC models for disease modeling and drug testing applications. Modular design principles (charcoal) can act as regulator to keep the two in balance.CC BY · PubMed Central

Verification

Claims the paper makes

38 Valid · 2 Not valid · 7 Not checked · 20 Own results and interpretations

27 more claims · 14 with their cited sources checked

Create a free account to see all 67 claims and to verify the 4 references still open.

See all claims — free account
  • It may state two separate claims as one. 25
  • Probably not a substantial claim. 13

Create a free account to see these claims.

Citations

Cites

Show all 61 references

Metadata

Authors
Hecking, J., Cano-Jorge, M., Passier, R., & Rivera-Arbeláez, J. M.
Affiliations
  • University of Twente (NL)
  • Leiden University Medical Center (NL)
Venue
Frontiers in Bioengineering and Biotechnology
Published
2026-01-05
Volume
13
Pages
1719533-1719533
ISSN
2296-4185 (ISSN-L)
OpenAlex
W7118192090
Cited by
0
References
60
FWCI
0.00
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Bioengineering and Biotechnology (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • University of Twente Research Information (publishedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • European Research Council (101098372)
  • Nederlandse Organisatie voor Wetenschappelijk Onderzoek (024003001)
  • Horizon Europe European Innovation Council (101070953)
Topics
  • Health Sciences › Medicine › Surgery › Tissue Engineering and Regenerative Medicine
  • Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Mechanical Circulatory Support Devices
Keywords
disease modeling, drug testing, cardiac organoids, engineered heart tissue, cardiac contractility, diastolic function, cardiac hemodynamics, modular design

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mini-hearts for disease modeling and drug testing – process optimization versus biological functionality. https://app.cochat.ai/papers/10.3389/fbioe.2025.1719533
The paper
Hecking, J., Cano-Jorge, M., Passier, R., & Rivera-Arbeláez, J. M. (2026). Mini-hearts for disease modeling and drug testing – process optimization versus biological functionality. Frontiers in Bioengineering and Biotechnology. https://doi.org/10.3389/fbioe.2025.1719533

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.